Investors & media

Financial data

Find the latest press releases, financial information, and performance updates.

Learn more

Transforming rare disease care

We are a global specialty biopharmaceutical company expanding possibilities for people with rare diseases. With 50 years of experience in applying our scientific expertise and unique technologies to research, we continue to develop next-generation treatments and expand our global footprint to transform the lives of patients worldwide.

Newsroom

2026.01.08
post image
JCR Pharmaceuticals to present at the 44th Annual J.P. Morgan Healthcare Conference
2026.01.23
Briefing session material on the agreement with Italfarmaco
2026.01.16
Information on the 44th J.P. Morgan Healthcare Conference now available
2026.01.16
The 44th J.P.Morgan Healthcare Conference presentation materials
2025.12.24
Italfarmaco and JCR Pharmaceuticals announce commercialisation agreement for Givinostat in Japan and strategic collaboration in rare disease
Subscribe

Stay informed with the latest company news, delivered straight to your inbox.

Get alerts

Performance data and annual reports

JCR Pharmaceuticals (4552.T)

Tokyo Currency in JPY

695.00

+13.00
(+1.91%)
Last updated 01/23/2026 at TSE market close

Company reports

Media toolkits

Two masked scientists in lab coats review data on a computer, microscope nearby

Driven by science and compassion, we tackle some of the most complex challenges in rare disease. Every solution we develop is grounded in insight into the genetic and biological foundations of the conditions we aim to treat.

View pipeline
Contact us

Investors & media